Margaret G. Mcglynn - 04 Mar 2024 Form 4 Insider Report for AMICUS THERAPEUTICS, INC. (FOLD)

Role
Director
Signature
/s/ Christian Formica, Attorney-in-Fact
Issuer symbol
FOLD
Transactions as of
04 Mar 2024
Net transactions value
-$158,175
Form type
4
Filing time
06 Mar 2024, 17:21:12 UTC
Previous filing
13 Jun 2023
Next filing
05 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FOLD Common Stock Options Exercise $21,000 +7,500 +13% $2.80 66,789 04 Mar 2024 Direct
transaction FOLD Common Stock Sale $99,675 -7,500 -11% $13.29 59,289 04 Mar 2024 Direct
transaction FOLD Common Stock Options Exercise $21,000 +7,500 +13% $2.80 66,789 05 Mar 2024 Direct
transaction FOLD Common Stock Sale $100,500 -7,500 -11% $13.40 59,289 05 Mar 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FOLD Stock Options (right to buy) Options Exercise $0 -7,500 -50% $0.000000 7,500 04 Mar 2024 Common Stock 7,500 $2.80 Direct F1
transaction FOLD Stock Options (right to buy) Options Exercise $0 -7,500 -100% $0.000000* 0 05 Mar 2024 Common Stock 7,500 $2.80 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 All of the options were fully vested and exercisable as of the transaction date.

Remarks:

All transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2023.